SLC6A3 and Parkinson disease: Confirming reduction of DAT density by single‐photon emission computed tomography in subjects with early motor deficit is proposed as a means of enriching future clinical trials of PD therapeutic agents as this facilitates excluding patients who are unlikely to show disease progression in a PD clinical trial.